Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.1. (Pharmacological Manipulation)
Study Details
Study Description
Brief Summary
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Participants with MDD or an anxiety disorder receiving the nociceptin receptor antagonist After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. Functional magnetic resonance imagining (fMRI) will begin 2 hours after the nociceptin receptor antagonist is administered. |
Drug: Nociceptin Receptor Antagonist
Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
Other Names:
Device: Aversive stimuli
As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
|
| Placebo Comparator: Participants with MDD or an anxiety disorder receiving the placebo After a diagnostic interview (determining the presence of MDD or an anxiety disorder) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered. |
Device: Aversive stimuli
As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
|
| Experimental: Healthy controls receiving the nociceptin receptor antagonist After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive a nociceptin receptor antagonist. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the nociceptin receptor antagonist is administered. |
Drug: Nociceptin Receptor Antagonist
Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
Other Names:
Device: Aversive stimuli
As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
|
| Placebo Comparator: Healthy controls receiving the placebo After a diagnostic interview (determining healthy control status) and collection of blood for Orphanin FQ/Nociceptin assays, participants will receive the placebo. Participants will then complete an approach/avoidance task. fMRI will begin 2 hours after the placebo is administered. |
Device: Aversive stimuli
As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
|
Outcome Measures
Primary Outcome Measures
- Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (SCID-5) [Baseline]
Diagnostic assessment
- Magnetic Resonance Imagining [Within 30 days of the clinical interview]
Both structural and functional brain images
- Approach/Avoidance Task [During the MRI scan]
A novel behavioral task assessing approach/avoidance decision-making
- Orphanin FQ/Nociceptin assays (using blood samples) [On the day of the MRI scan]
Measure of Orphanin FQ/Nociceptin
Secondary Outcome Measures
- Beck Depression Inventory-II [Baseline, 6-month follow-up, 12-month follow-up]
21-item measure of depression severity; scores range from 0 to 63; higher scores indicate higher depression severity
- Hamilton Rating Scale for Depression [Baseline, 6-month follow-up, 12-month follow-up]
17-item measure of depression severity; scores range from 0 to 34; higher scores indicate higher depression severity
- Perceived Stress Scale [Baseline, 6-month follow-up, 12-month follow-up]
14-item measure of stress appraisal; scores range from 0 to 56; higher scores indicate higher perceived stress
- Snaith Hamilton Pleasure Scale [Baseline, 6-month follow-up, 12-month follow-up]
14-item measure of anhedonia; scores range from 14 to 56; higher scores indicate higher anhedonia
- Medical Outcome Survey- Short Form [Baseline, 6-month follow-up, 12-month follow-up]
36-item measure of physical and social functioning; score range from 36 to 149; higher scores indicate higher physical and social functioning
- Quality of Life Enjoyment and Satisfaction Questionnaire [Baseline, 6-month follow-up, 12-month follow-up]
16-item measure of satisfaction and enjoyment across domains (e.g., work, interpersonal); scores range from 16 to 80; higher scores indicate higher life enjoyment and satisfaction
- Temporal Experience of Pleasure Scale [Baseline, 6-month follow-up, 12-month follow-up]
24-item measure of anticipatory and consummatory pleasure; scores range from 24 to 144; higher scores indicate higher anticipatory/consummatory pleasure
- Life Events and Difficulties Schedule [Baseline, 6-month follow-up, 12-month follow-up]
Measure of acute events, difficulties, stressors
- Longitudinal Interval Follow-Up Evaluation (LIFE) (Keller et al., 1987) [6-month follow-up, 12-month follow-up]
Retrospectively assesses different DSM-5 disorders, social and occupational functioning, and life satisfaction over the past 6 months
- Columbia-Suicide Severity Rating Scale [Baseline, 6-month follow-up, 12-month follow-up]
Suicide assessment
Eligibility Criteria
Criteria
Inclusion criteria for MDD/anxiety disorder group:
-
DSM-5 diagnostic criteria for MDD, Generalized Anxiety Disorder, Social Phobia, Panic Disorder, Post Traumatic Stress (diagnosed using the SCID-5)
-
Written informed consent
-
For MDD subjects, a baseline Hamilton Depression Rating Scale score > 16 (17-item version)
-
Right-handed
-
Has a smartphone (iPhone or Android) (needed for Ecological Momentary Assessment)
-
Absence of any psychotropic medications for at least 2 weeks (6 weeks for fluoxetine, 6 months for neuroleptics, 2 weeks for benzodiazepines, 2 weeks for any other antidepressants)
Inclusion criteria for healthy controls:
-
Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by subject history and a structured clinical interview (diagnosed using the SCID-5)
-
Written informed consent
-
Right-handed
-
Absence of any medications for at least 3 weeks
-
Has a smartphone (iPhone or Android) (needed for Ecological Momentary Assessment)
Exclusion criteria for all participants:
-
Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician
-
Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception
-
Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease
-
History of seizure disorder
-
History or current diagnosis of any of the following DSM-IV psychiatric illnesses: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, obsessive-compulsive disorder, patients with mood congruent or mood incongruent psychotic features, substance dependence, substance abuse within the last 12 months (with the exception of cocaine or stimulant abuse; which will lead to exclusion)
-
History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine)
-
History of use of dopaminergic drugs (including methylphenidate)
-
History or current diagnosis of dementia
-
Patients with mood congruent or mood incongruent psychotic features
-
Current use of other psychotropic drugs
-
Clinical or laboratory evidence of hypothyroidism
-
Patients with a lifetime history of electroconvulsive therapy
-
Failure to meet standard magnetic resonance imaging safety requirements
-
Abnormal ECG and lab results
-
History of seizure disorder or currently on anticonvulsants
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Mclean Hospital
- National Institute of Mental Health (NIMH)
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- University of Washington
- Brown University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 5P50MH119467-02
- 5P50MH119467-02